BioSpace News Archive

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and ene

Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, MD, has been appointed to the company’s Board of Directors effective immediately. “In 2020, Enzo reported significant progress in advancing our business plan to achieve profitability including strong results in many areas of our operations that position us for new levels of growth and momentum in 2021

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that members of management will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19th, 2020.

Surgeons’ preoperative expectations were more accurate than patients’ expectations in predicting patient-reported outcomes two years after lumbar spine surgery, according to a longitudinal study by investigators at Hospital for Special Surgery.

Jardiance® (empagliflozin) reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and established cardiovascular disease over the three years of the EMPA-REG OUTCOME® trial, according to results of a new post-hoc analysis

AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced the appointment of Dennis D. Kim, M.D., MBA, as chief medical officer.

Heska Corporation, a leading global provider of advanced veterinary diagnostic and specialty products, appointed Robert L. Antin, the Founder of VCA Antech, Inc., to the Company’s Board of Directors, effective November 17, 2020.

Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body’s antitumor immunity by altering the composition and function

Following 9-months of treatment with PrimeC, NeuroSense’s combination drug, positive trends first seen in the 6-month interim analysis persist, indicating therapeutic potential for ALS patients.

Submitted Investigational Device Exemption (IDE) application to the FDA for Pivotal Study of C-Scan®